Related Experiment Video
Updated: Oct 25, 2026
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in
M Ständer1, U Naumann, L Dumitrescu
1Department of Neurology, University of Tuebingen, Germany.
Abstract:
Cytokines such as transforming growth factor-beta (TGF-beta) are thought to mediate escape from immune surveillance in human malignant glioma. Here, we report that ectopic expression of the small TGF-beta-binding proteoglycan, decorin, inhibits not only TGF-beta bioactivity but also TGF-beta 1 and TGF-beta 2 mRNA transcription and TGF-beta protein synthesis by human LN-18, LN-229, T98G and rat C6 glioma cells in vitro. Ectopic expression of decorin in C6 rat glioma cells results in strong inhibition of tumor formation in vivo. Decorin-expressing C6 gliomas grow initially but regress to very small residual tumors at 12 weeks after implantation whereas all control animals die or have to be killed within 4 weeks. Decorin-expressing tumors show a four-fold increase of infiltration by activated T cells and a 1.6-fold increase in total B and T cells. Chronic steroid-mediated immunosuppression abrogates the inhibitory effects of decorin gene transfer. We conclude that decorin-induced inhibition of TGF-beta release by glioma cells significantly enhances antiglioma immune responses in vivo. Clinical evaluation of decorin gene therapy for human malignant gliomas may be warranted.
Insights
Decorin gene therapy inhibits transforming growth factor-beta (TGF-beta) production in glioma cells, enhancing anti-tumor immune responses and leading to significant tumor regression in vivo.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Malignant gliomas often evade immune surveillance through cytokines like transforming growth factor-beta (TGF-beta).
- Targeting TGF-beta signaling is a potential strategy for enhancing anti-glioma immunity.
Purpose of the Study:
- To investigate the effect of decorin, a TGF-beta binding proteoglycan, on TGF-beta production and glioma growth.
- To evaluate the potential of decorin gene therapy in enhancing anti-glioma immune responses.
Main Methods:
- Ectopic expression of decorin in human and rat glioma cell lines (LN-18, LN-229, T98G, C6).
- In vitro assessment of TGF-beta bioactivity, mRNA transcription, and protein synthesis.
- In vivo studies using C6 rat glioma cells in immunocompetent rats, with and without immunosuppression.
Main Results:
- Decorin expression inhibited TGF-beta bioactivity, mRNA, and protein synthesis in glioma cells.
- In vivo, decorin-expressing C6 gliomas showed significant regression compared to controls.
- Decorin-treated tumors exhibited increased infiltration of T cells and B cells, indicating enhanced immune response.
- Immunosuppression abrogated the anti-tumor effects of decorin, confirming the immune-mediated mechanism.
Conclusions:
- Decorin gene therapy effectively suppresses TGF-beta production by glioma cells.
- Decorin enhances anti-glioma immune responses, leading to tumor regression.
- Decorin gene therapy represents a promising therapeutic strategy for malignant gliomas.
